Ind-Swift Laboratories has fixed the issue price for its preferential allotment of warrants at ₹196 each. The Preferential Issue Committee approved the pricing during a meeting held on September 4, 2026, following shareholder approval at an Extra-Ordinary General Meeting on August 5, 2026.

The final issue price exceeds both the regulatory floor price and the independent valuation estimate. Under Regulation 164 of the SEBI ICDR Regulations, 2018, the minimum floor price was determined to be ₹195.98, based on the higher of the 90-day volume-weighted average price (₹154.48) and the 10-day volume-weighted average price (₹195.98) preceding the relevant date of July 6, 2026.

Pricing Methodology

The company followed a multi-step pricing framework mandated by SEBI regulations due to the issuance representing more than five percent of the post-issue fully diluted share capital. The final price was derived from three distinct benchmarks:

An independent valuation report by Corporate Professionals Valuation Services Private Limited placed the warrant value at ₹189.46. However, SEBI Regulation 166A requires the minimum issue price to be the higher of the price determined under Regulation 164 or the valuation report. Consequently, the regulatory floor stood at ₹195.98.

What the Numbers Show

The board’s decision to set the issue price at ₹196 represents a premium of just ₹0.02 over the strict regulatory floor. This minimal margin suggests the company prioritized compliance efficiency and investor certainty over maximizing immediate capital raise per unit, likely to ensure swift allotment completion. The significant divergence between the 90-day average (₹154.48) and the 10-day average (₹195.98) indicates notable volatility in the stock’s trading price leading up to the relevant date, with recent trading activity driving the floor price significantly higher than longer-term trends.

All other particulars in the Explanatory Statement to the EGM Notice remain unchanged. The company is listed on the National Stock Exchange of India Limited and BSE Limited.

Ind-Swift Laboratories management has guided for ₹900 crore revenue and sustainable EBITDA margins of over 18% for FY27. The company also outlined a longer-term roadmap targeting ₹1,500 crore revenue and ₹200 crore profit after tax by FY30.

Revenue and profitability targets

The company has outlined a medium-term financial plan anchored by two key milestones. The near-term goal focuses on FY27, while the longer-term ambition extends to FY30. The following table summarises the disclosed targets:

For FY27, Ind-Swift Laboratories is targeting ₹900 crore in revenue alongside EBITDA margins exceeding 18%. By FY30, the company aims to scale revenue to ₹1,500 crore and deliver a profit after tax of ₹200 crore.